Evolution of systemic treatment for advanced hepatocellular carcinoma
Journal
Kaohsiung Journal of Medical Sciences
Journal Volume
37
Journal Issue
8
Pages
643-653
Date Issued
2021
Author(s)
Abstract
Advanced hepatocellular carcinoma (HCC) was considered an inherently refractory tumor in the chemotherapy era (1950–2000). However, systemic therapy has evolved to molecular targeted therapy and immunotherapy, and nine treatment regimens have been approved worldwide during the past 20 years. The approved regimens target tumor angiogenesis or tumor immunity, the two cancer hallmarks. Recently, the combination of atezolizumab (antiprogrammed cell death ligand 1) and bevacizumab (anti-vascular endothelial growth factor) has improved the efficacy of systemic therapy in treating advanced HCC without excessive toxicities or deterioration of quality of life. This review summarizes the major advances in systemic therapy and provides future perspectives on the next-generation systemic therapy for advanced HCC. ? 2021 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.
SDGs
Other Subjects
angiogenesis inhibitor; antineoplastic agent; antineoplastic monoclonal antibody; cytotoxic agent; cytotoxic T lymphocyte antigen 4 antibody; gilvetmab; immune checkpoint inhibitor; unclassified drug; vasculotropin receptor inhibitor; angiogenesis inhibitor; antineoplastic agent; advanced cancer; antiangiogenic therapy; cancer chemotherapy; cancer combination chemotherapy; cancer immunotherapy; history of medicine; human; liver cell carcinoma; molecularly targeted therapy; monoclonal antibody therapy; Review; systemic therapy; immunotherapy; liver cell carcinoma; liver tumor; procedures; vascularization; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy
Publisher
John Wiley and Sons Inc
Type
review